lapatinib
Selected indexed studies
- Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs. (Sci Rep, 2022) [PMID:35027594]
- Lapatinib. (Recent Results Cancer Res, 2018) [PMID:30069757]
- PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. (Cancer Lett, 2024) [PMID:38986734]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs. (2022) pubmed
- Lapatinib. (2018) pubmed
- PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. (2024) pubmed
- Lapatinib in breast cancer. (2007) pubmed
- Lapatinib side-effect management. (2010) pubmed
- Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis. (2022) pubmed
- Lapatinib: A comprehensive profile. (2023) pubmed
- HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis. (2020) pubmed
- Lapatinib: a sword with two edges. (2008) pubmed
- [Lapatinib treatment-option in trastuzumab-resistant breast cancer]. (2009) pubmed